Biotechnology Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy – Ocugen (NASDAQ:OCGN) Read more
Biotechnology Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 – Ocugen (NASDAQ:OCGN) Read more
Biotechnology Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children – Novartis (NYSE:NVS) Read more